Multiple myeloma (MM) is the second most frequent hematologic cancer in the United States. Carfilzomib (CFZ), an irreversible proteasome inhibitor being used to treat relapsed and refractory MM, has been associated with cardiotoxicity, including heart failure. We hypothesized that a multi-omics approach integrating data from different omics would provide insights into the mechanisms of CFZ-related cardiovascular adverse events (CVAEs). Plasma samples were collected from 13 MM patients treated with CFZ (including 7 with CVAEs and 6 with no CVAEs) at the University of Florida Health Cancer Center. These samples were evaluated in global metabolomic profiling, global proteomic profiling, and microRNA (miRNA) profiling. Integrative pathway analysis was performed to identify genes and pathways differentially expressed between patients with and without CVAEs. The proteomics analysis identified the up-regulation of lactate dehydrogenase B (LDHB) [fold change (FC) = 8.2, p = 0.01] in patients who experienced CVAEs. The metabolomics analysis identified lower plasma abundance of pyruvate (FC = 0.16, p = 0.0004) and higher abundance of lactate (FC = 2.4, p = 0.0001) in patients with CVAEs. Differential expression analysis of miRNAs profiling identified mir-146b to be up-regulatein (FC = 14, p = 0.046) in patients with CVAE. Pathway analysis suggested that the pyruvate fermentation to lactate pathway is associated with CFZ-CVAEs. In this pilot multi-omics analysis of miRNAs profiling identified mir-146b to be up-regulatein (FC = 14, p = 0.046) in patients with CVAE. Pathway analysis suggested that the pyruvate fermentation to lactate pathway is associated with CFZ-CVAEs. In this pilot multi-omics
INTRODUCTION

Multiple myeloma (MM) is a malignant plasma cell disorder and is the second most frequent hematologic cancer in the United States (1). Proteasome inhibitors (PIs) are among the most important classes of drugs to treat newly diagnosed, relapsed, and refractory MM (2). The mechanism of PI is dependent on the inhibition of proteasomal activity that disrupts the cell signaling pathways and leads to apoptosis and cell death (3, 4). So far, three PIs, bortezomib (Velcade®), carfilzomib (CFZ, Kyprolis®), and ixazomib (Ninlaro®), have been approved by the United States Food and Drug Administration (FDA) (5). CFZ is a second-generation PI that irreversibly inhibits 20S proteasome and is FDA-approved to treat relapsed or refractory MM patients who have received one to three previous treatments for MM. MM patients treated with CFZ and dexamethasone had improved survival compared with those treated with bortezomib and dexamethasone (6, 7).

Patients with MM often have cardiovascular diseases (CVDs) that may be a result of factors unrelated to MM, including older age, diabetes, obesity, or factors related to MM (such as amyloidosis), and other factors associated with the treatment of MM (such as anthracyclines, corticosteroids, alkylating agents, and PIs) (8). In an interim analysis of the phase 3 ENDEAVOR study, CFZ resulted in a significant and clinically meaningful survival benefit in relapsed MM patients compared with bortezomib, but it also was associated with significantly higher grade 3 cardiotoxicity, including heart failure (HF). In two meta-analyses, CFZ was associated with an increased incidence of cardiovascular adverse events (CVAEs) (8–18%) (2, 5) including hypertension, HF, arrhythmia, and cardiomyopathy (9, 10). CFZ accumulates in the heart, causes potent inhibition of the cardiac proteasome, and also decreases the 20S chymotrypsin-like activity to 10% in cardiomyocytes and 45% in bone marrow cells within 5 min after administration (11). Clinical trials and real-world experiences reported increasing incidence of CVAEs due to CFZ (CFZ-CVAE) in patients with MM compared with patients without MM with an adjusted hazard ratio (HR) ranging from 1.74 to 4.09 (8), which led to hospitalization, discontinuation of CFZ treatment, and also treatment-related death in ∼5% of patients (12, 13). A critical clinical implication of this cardiotoxicity is treatment interruption that is associated with cancer recurrence (14). So far, there has been no human study investigating the mechanisms of CFZ-CVAE nor germline genetic risk factors for CFZ-CVAE. An integrative approach that combines multi-omics data, such as metabolomics, proteomics, transcriptomics, and microRNA (miRNA), may provide important insights into complex biological processes related to CFZ-CVAE.

This pilot study aimed to explore an integrative multi-omics approach to investigate data from different omics platforms including proteomics, metabolomics, and miRNAs to gain insights into the molecular mechanisms of CFZ-CVAE in MM patients.

MATERIALS AND METHODS

Patients

The study was a retrospective cohort study of MM patients treated with CFZ at the University of Florida Health Cancer Center. Post-treatment whole blood samples were collected from MM patients who provided consent. CVAEs were evaluated in patients who had HF symptoms that led to obtaining the echocardiography and were confirmed by a cardiologist. A total of 13 MM patients were analyzed, including 7 who experienced CVAEs. This study was approved by the University of Florida Institutional Review Board (IRB) (IRB# 201702876).

Global Metabolomic Profiling

Global metabolomic profiling of plasma samples was performed on a Thermo Q-Exactive Orbitrap mass spectrometer coupled with ultra-high-performance liquid chromatography (UHPLC) at the Southeast Center for Integrated Metabolomics at the University of Florida. Details of the analytical method are described in the method section of the Supplementary Materials. All metabolites from positive and negative ion modes were separately subjected to quality control steps, data normalization, and statistical analyses using Metabo Analyst 4.0 (15, 16). T-test and partial least square discrimination analysis (PLS-DA) were performed to identify metabolites with different abundance in those with and without CVAEs. Known metabolites with fold change (FC) of >1.5 and raw p-value of <0.001 were selected for pathway analysis using Ingenuity Pathway Analysis (IPA) (Qiagen IPA, USA).

Global Proteomics Profiling

Global proteomic profiling was performed on the plasma samples using the isobaric tags for relative and absolute quantification (iTRAQ) high-throughput proteomic method on these 13 MM patients treated with CFZ to identify proteomic biomarkers associated with CFZ-CVAEs. For quantification, only MS/MS spectra that were unique to a particular peptide and the sum of the signal-to-noise ratios for all the peak pairs >9 were used. The ratios with p < 0.05 present in at least two replicates.
were considered significant. Only the significant ratios from the replicates were used to calculate the average ratio for the protein. Details of the analytical method are described in the Method section of the Supplementary Materials.

Circulating miRNA Extraction and Profiling
Total RNA was extracted from the plasma samples using the miRVana microRNA Isolation Kit (Thermo Fisher Scientific, USA) and reverse transcribed using Megaplex™ RT Primers. Preamplification of cDNA with Megaplex™ PreAmp primers was performed according to the manufacturer's protocol and recommendations (Thermo Fisher Scientific, USA). miRNA expression was quantified using TaqMan® recommendations (Thermo Fisher Scientific, USA). miRNA was performed according to the manufacturer's protocol and recommendations (Thermo Fisher Scientific, USA). miRNA expression was quantified using TaqMan® recommendations (Thermo Fisher Scientific, USA). miRNA was performed according to the manufacturer's protocol and recommendations (Thermo Fisher Scientific, USA).

Statistical Analysis
The characteristics of the patients were summarized with mean and standard deviation, median and range, or number and percentages as appropriate. The characteristics of patients with and without CV AEs were compared using Fisher's exact test for categorical variables and Mann–Whitney U test for continuous variables.

The high-throughput data generated from TaqMan® OpenArray® RT-qPCR, the miRNAs with Cq-values above 35, and the amplification score below 1.24 were excluded. The combination of miR-24 and miR-16 was used for normalization according to the NormFinder software suggestion with the most stable value of 0.005 (17). MiRNAs were determined to be significantly up- or down-regulated in MM samples with CV AEs and FC >1.5 or <0.5, p ≤ 0.05; the 2^−ΔΔCT method was used for analysis (18). All statistical analyses were performed using SAS v.9.4 (Cary, NC, USA), Statistical Package for the Social Sciences SPSS v.26 (IBM Corp., USA), or R software.

Multi-Omics Integrative Analysis and Prediction of Biological Functions and Networks
The canonical pathways and networks associated with the differentially expressed metabolites, proteins, and miRNAs were identified using Qiagen's Ingenuity® Pathway Analysis version 6.0 (IPA® QIAGEN Bioinformatics, CA, USA; www.qiagen.com/ingenuity). IPA helps to predict the biological activity across thousands of datasets that represent disease conditions. By incorporating the top proteins, metabolites, and miRNAs, the canonical pathways associated with the multi-omics data can be identified. The pathways enriched with the top signals in any of the multi-omics data sources were identified using Fisher's exact test.

RESULTS
A total of 13 MM patients treated with CFZ were analyzed, including 7 (53.8%) who experienced CV AEs. The overall median age was 58 years (range 46–76), and 38.5% were men. The characteristics of patients with or without CV AEs are summarized in Table 1. There were no statistical differences in demographics, comorbidities, or MM status between the patients who developed CV AEs and those who did not. There was no significant difference in baseline left ventricular ejection fraction (LVEF) between the two groups. However, there was a trend of lower LVEF in patients with CV AEs (median 32.5) than in those without CV AEs (median 57.5) (p = 0.08).

Metabolomic Profiling
A total of 8,636 metabolites were identified in the untargeted metabolomic profiling. After quality control, a total of 375 known metabolites were analyzed. The PLS-DA scores plots indicated a good separation of metabolites between patients with and without CV AEs (Figures 1A,B). Seventeen metabolites had FC >1.5 and raw p < 0.001. The top 25 metabolites that differentiated these two groups of patients in positive and negative ionization are illustrated in the heatmaps (Figures 1C,D). Among the top metabolites, lower intensities of lysophospholipids were identified in patients with CV AEs compared with patients without CV AEs. For example, the abundance of lysophosphatidylcholines [LysoPC (18:3), HMDB0010387] in patients with CV AEs was 33% of that in patients without CV AEs (p = 0.0003). The abundance of LysoPC (20:3, HMDB0010393) in patients with CV AEs was 39% of that in patients without CV AEs (p = 0.0005). The abundance of lysophosphatidylethanolamine [LysoPE (20:3), HMDB0011515] in patients with CV AEs was 44% of that as compared with patients without CV AEs (p = 0.0005) (Figures 2A–C).

Additionally, the metabolomics data analysis identified lower abundance of pyruvic acid (HMDB000243) in patients with CV AEs as 16% of that seen in patients without CV AEs (p = 0.0004), but an increased abundance of the lactate modified amino acid (N-lactoyl-methionine, HMDB0062182) (2.4-fold) in

| TABLE 1 | Demographic and clinical characteristics of patients treated with CFZ. |
|----------|-------------------------------------------------|
| CV AEs (n = 7) | No CV AEs (n = 6) | p-value |
| Age, years (mean ± SD) | 64 ± 9.4 | 55.5 ± 9.7 | 0.22 |
| Male sex, | 2 (28.5%) | 3 (50%) | 0.59 |
| Diabetes | 2 (28.5%) | 0 | 0.46 |
| Hypertension | 3 (43%) | 6 (100%) | 0.07 |
| Hyperlipidemia | 2 (28.5%) | 2 (33.4%) | 0.99 |
| Chronic kidney disease | 2 (28.5%) | 2 (33.4%) | 0.99 |
| Baseline LVEF, median (minimum; maximum) | 55 (50–65) | 62.5 (55–65) | 0.44 |
| Follow-up LVEF, median (minimum; maximum) | 32.5 (20–60) | 57.5 (50–67.5) | 0.08 |
| MM status | | | |
| Complete remission | 3 (43%) | 2 (33.5%) | 0.99 |
| Partial remission | 1 (14%) | 1 (16.5%) | |
| Relapsed/progressive disease | 3 (43%) | 3 (50%) | |

CV AEs, cardiovascular adverse event; SD, standard deviation; LVEF, left ventricular ejection fraction; MM, multiple myeloma. Categorical variables are summarized as n (%). p-values were from Fisher’s exact test for categorical variables and Mann–Whitney U test for continuous variables.
patients with CVAEs compared with the abundance in patients without CVAEs ($p = 0.0001$) (Figures 2D,E). All top metabolites that differentiated patients with and without CVAEs (with FC $>1.5$ or $<0.5$, $p < 0.01$) are listed in Table 2.

**Proteomic Profiling**

From a total of 374 identified proteins, 347 were quantified with 202 excluded due to variation within the non-CVAE group. Fifty-seven proteins were differentially expressed, including 12 proteins down-regulated and 45 up-regulated in MM patients with CVAEs compared with those without CVAEs (FC $>1.5$ or $<0.5$, $p < 0.05$) (Table 3). The differential expression between the two groups is presented in the volcano plot (Figure 3). The top proteins that were up-regulated in patients with CVAEs compared with those without CVAEs include complement factor D (CFD) (FC = 6.15, $p = 0.0006$), lactate dehydrogenase B (LDHB) (FC = 8.24, $p = 0.015$), and insulin-like growth factor-binding protein 2 (IGFBP2) (FC = 7.67, $p = 0.0017$) (Table 3).
MiRNA Profiling

TaqMan OpenArray analyzed a total of 750 miRNAs in 13 MM patients treated with CFZ. Twenty-one of these miRNAs were identified to be up-regulated or down-regulated in patients with CVAEs compared with patients without CVAEs (Table 4). Figure 4 shows the volcano plot of the OpenArray miRNAs data that were up-regulated or down-regulated in MM patients with CVAEs compared with those without CVAEs. Differential expression analysis of miRNAs profiling identified mir-146b to be up-regulated in those with CVAEs compared with those without CVAEs (FC = 14, \( p = 0.046 \)).
TABLE 2 | Top metabolites that differentiate patients with and without CVAEs (with fold change > 1.5 or < 0.5 and p < 0.01).

| HMDB ID          | Metabolite name                                      | Fold change | p-value       |
|------------------|------------------------------------------------------|-------------|---------------|
| HMDB0028983      | Methionyl-threonine                                   | 0.19        | 0.00008       |
| HMDB0062182      | N-lactoyl-methionine                                  | 2.38        | 0.00014       |
| HMDB0010387      | LysoPC (18:3(9Z,12Z)/0:0)                            | 0.33        | 0.00032       |
| HMDB0000243      | Pyruvic acid                                          | 0.16        | 0.00049       |
| HMDB0010389      | LysoPC (20:3(5Z,8Z,11Z)/0:0)                         | 0.39        | 0.00053       |
| HMDB0011515      | LysoPE (20:3(5Z,8Z,11Z)/0:0)                         | 0.44        | 0.00055       |
| HMDB0002894      | 5-Methylcytosine                                      | 1.97        | 0.00085       |
| HMDB0000277      | Sphingosine-1-phosphate                               | 0.31        | 0.00133       |
| HMDB0062181      | N-Lactoylvaline                                       | 2.29        | 0.00144       |
| HMDB0032842      | 5-Methyl-5-pentacosanol                               | 2.70        | 0.00145       |
| HMDB0000933      | Traumatic acid                                        | 1.98        | 0.00163       |
| HMDB0010379      | LysoPC (14:0/0:0)                                     | 0.37        | 0.00188       |
| HMDB0010384      | LysoPC (18:0/0:0)                                     | 0.40        | 0.00911       |
| HMDB0010385      | LysoPC (18:3(6Z,9Z,12Z)/0:0)                         | 0.33        | 0.00936       |
| HMDB0002870      | S-Methylmethionine                                    | 0.19        | 0.00975       |
| HMDB0000574      | 1-Methylguanosine                                     | 2.16        | 0.00977       |
| HMDB0030245      | 2-Pentenoic acid                                      | 2.38        | 0.00977       |
| HMDB0000469      | Linoleyl carnitine                                    | 0.12        | 0.00539       |
| HMDB0002234      | Thiamine                                              | 0.12        | 0.00539       |
| HMDB0000218      | LysoPC (18:2(9Z,12Z)/0:0)                            | 0.38        | 0.00623       |
| HMDB0000574      | γ-Aminobutyric acid                                   | 0.21        | 0.00673       |
| HMDB0011502      | LysoPE (15:0/0:0)                                     | 0.39        | 0.00911       |
| HMDB0030245      | 1-Methylguanosine                                     | 2.16        | 0.00977       |
| HMDB0010012      | LysoPC(22:5(4Z,7Z,10Z,13Z,16Z)/0:0)                   | 0.49        | 0.00923       |
| HMDB0034355      | 3-Hydroxymethyl-2-furancarboxaldehyde                 | 1.54        | 0.00982       |
| HMDB0006469      | Thiamine                                              | 0.12        | 0.00539       |
| HMDB0000218      | LysoPC (18:2(9Z,12Z)/0:0)                            | 0.38        | 0.00623       |
| HMDB0010012      | LysoPC(22:5(4Z,7Z,10Z,13Z,16Z)/0:0)                   | 0.49        | 0.00923       |
| HMDB0000933      | Traumatic acid                                        | 1.98        | 0.00163       |
| HMDB0010379      | LysoPC (14:0/0:0)                                     | 0.37        | 0.00188       |
| HMDB0010386      | LysoPC (18:2(9Z,12Z)/0:0)                            | 0.38        | 0.00623       |
| HMDB0030245      | 2-Pentenoic acid                                      | 2.38        | 0.00977       |
| HMDB0000469      | Linoleyl carnitine                                    | 0.12        | 0.00539       |
| HMDB0000218      | LysoPC (18:2(9Z,12Z)/0:0)                            | 0.38        | 0.00623       |
| HMDB0010012      | LysoPC(22:5(4Z,7Z,10Z,13Z,16Z)/0:0)                   | 0.49        | 0.00923       |
| HMDB0034355      | 3-Hydroxymethyl-2-furancarboxaldehyde                 | 1.54        | 0.00982       |

Pathway Analysis Using IPA

The top proteins and metabolites that were differentially expressed in the two groups were incorporated into the IPA analysis. The top two most significant canonical pathways associated with CFZ-CVAEs are the glutamate-dependent acid resistance pathway (p = 0.006) and pyruvate fermentation to lactate pathway (p = 0.01).

DISCUSSION

In this pilot study, we performed integrative multi-omics analyses of metabolomic, proteomic, and miRNA data to identify differences among MM patients with or without CVAEs. Up-regulation of LDHB, lower plasma abundance of pyruvate, higher plasma abundance of lactate, and up-regulation of mir-146b were observed in patients with CVAEs compared with those without CVAEs. The most significant pathway identified was the glutamate-dependent acid resistance pathway that is related to fatty acid biotransformation activity. (19) The second top significant pathway, the pyruvate oxidation pathway, was related to mitochondrial dysfunction (20).

Mitochondria is the active organelle that produces the most reactive oxygen species (ROS) that leads to peroxidation of lipids and DNA damage in cardiomyocytes (21–23). In cardiac cells, the LDHB converts lactate to pyruvate, which is considered the critical metabolite in glycolysis and glucose oxidation. The pyruvate oxidation (pyruvate decarboxylation) occurs after pyruvate is converted to acetyl-CoA in the mitochondria by the pyruvate dehydrogenase complex (PDC). Acetyl-CoA then is used in the citric acid cycle (CAC) for adenosine triphosphate (ATP) production, which is essential for cardiomycyte contractility (24). The decarboxylation of pyruvate is dominant in the mitochondria of healthy cardiac cells (24). Mitochondrial protein complex (MPC) is a mitochondrial inner-protein complex that consists of two subunits: MPC1 and MPC2. Both subunits are essential for the normal function of MPC, and loss of any subunit would affect the mitochondrial pyruvate transport and the pyruvate supporting the oxygen consumption in cardiac cells (25). A recent study identified a correlation between LDHB and cardiac hypertrophy and suggested a molecular mechanism for regulating abnormal energy metabolism in cardiac hypertrophy (26–28). Based on our preliminary results, there was compelling evidence for the pyruvate oxidation pathway's involvement in CFZ-CVAEs.

A previous study of mice published by Efentakis and colleagues suggested that CFZ induces cardiotoxicity through increased protein phosphatase 2 (PP2A) activity and inhibition of AMP-activated protein kinase (AMPK) and its downstream autophagic targets (4). Our untargeted metabolomic analyses identified significantly lower abundance of phospholipids, such as LysoPC. In another study in non-cancer patients with Heart Failure Reduced Ejection Fraction (HFrEF), the authors also found decreasing phospholipids compared with healthy controls matched by age, sex, body mass index, and ischemic heart disease status (29). Lower lysophospholipid levels coupled with higher long-chain acylcarnitine levels may reflect a shift toward increased myocardial glucose oxidation, with down-regulation of fatty acid oxidation as the result of mitochondrial dysfunction in HF patients. Lower lysophospholipid levels result from increased PP2A activity, which is an essential and ubiquitously expressed serine–threonine phosphatase, plays a critical role in cellular processes, such as cell proliferation and apoptosis, and is responsible for more than 90% of protein dephosphorylation in cardiac cells (30, 31). Studies have shown that lower levels of lysophospholipids are likely to increase PP2A activity (32) and inhibition of AMPK (33). Our findings of metabolomic readout of MM patients treated with CFZ were consistent with a previously published study in mice.
TABLE 3 | The list of a total of 57 differentially expressed proteins at <0.5 or >1.5 of fold changes with p < 0.05.

| UniProt ID | Protein name | Fold change | p-value |
|------------|--------------|-------------|---------|
| F8WA32     | Testis-specific gene 10 protein (Fragment) | 12.69 | 0.00001 |
| K7ERG9     | Complement factor D | 6.15 | 0.00006 |
| H0YS28     | Transmembrane protein 19 (Fragment) | 0.15 | 0.00012 |
| P05543     | Thyroxine-binding globulin | 9.90 | 0.00027 |
| P18065     | Insulin-like growth factor-binding protein 2 | 7.67 | 0.00169 |
| Q9YSZ9     | UbA prenyltransferase domain-containing protein 1 | 1.61 | 0.00012 |
| Q8N601     | EH domain-binding protein 1 | 1.77 | 0.00252 |
| B3KT8      | cDNA FLJ373865 fis, clone BRHIP2013972 | 0.27 | 0.00288 |
| Q96L14     | Cep170-like protein | 0.07 | 0.00308 |
| A0A087VZT2 | Methyltransferase-like protein 7B | 0.25 | 0.00341 |
| A6NGC6     | Retinitis pigmenta 1-like 1 protein | 2.84 | 0.00465 |
| Q9Y2Z9     | Ubiquitene biosynthesis monoxygenase COQ6, mitochondrial | 0.42 | 0.00473 |
| Q8Q107     | IGL@ protein | 3.62 | 0.00489 |
| O60692     | Kelch-like protein 41 | 0.41 | 0.00504 |
| A0A087WVH3 | BRD4-interacting chromatin-remodeling complex-associated protein | 0.38 | 0.00524 |
| A0A125QYY5 | Voltage-dependent P/Q-type calcium channel subunit alpha | 0.26 | 0.00707 |
| A0A125QYY5 | Voltage-dependent P/Q-type calcium channel subunit alpha | 0.26 | 0.00707 |

TABLE 3 | Continued

| UniProt ID | Protein name | Fold change | p-value |
|------------|--------------|-------------|---------|
| Q96K0      | Secreted phosphoprotein 24 (Fragment) | 6.61 | 0.02618 |
| A0A024RAQ6 | Complement component 1, q subcomponent, A chain, isoform CRA_a | 5.65 | 0.02649 |
| Q7Z379     | Uncharacterized protein | 1.63 | 0.02666 |
| Q86TT1     | Full-length cDNA clone CS0D006Y102 | 3.14 | 0.02779 |
| Q8IMJ8     | NOELIN1_V1 | 7.97 | 0.02800 |
| B1AH2      | Fibulin-1 | 2.11 | 0.02931 |
| A2J422     | Anti-HER3 scFv (Fragment) | 3.07 | 0.02943 |
| A0A187871U | Sulfhydryl oxidase 1 | 4.50 | 0.03095 |
| P23142     | Fibulin-1 | 2.45 | 0.03207 |
| Q15075     | Early endome antigen 1 | 2.50 | 0.03218 |
| Q8BQX1     | PHR protein (Fragment) | 2.59 | 0.03423 |
| A0A187871U | Sulfhydryl oxidase 1 | 4.50 | 0.03095 |
| A0A24RAQ6  | Complement component 1, q subcomponent, A chain, isoform CRA_a | 5.65 | 0.02649 |
| Q7Z379     | Uncharacterized protein | 1.63 | 0.02666 |
| Q86TT1     | Full-length cDNA clone CS0D006Y102 | 3.14 | 0.02779 |

We also discovered the CFD to be significantly up-regulated in patients with CVAEs. CFD is targeted by miR-17, miR-19b, miR-92a, miR-30b,c, and miR-106a (34). CFD also promotes the alternative pathway complement (AP) activation, and the complement activation was shown to occur in chronic HF and is associated with adverse clinical events (35). These findings suggest that CFZ may induce cardiac dysfunction via increasing CFD activity, leading to the complement system’s activation. We also observed an elevation of IGFBP2 in patients who experienced CVAEs. Previous studies reported that IGFBP2 might play an essential role as a potential diagnostic and prognostic marker for suspected HF (30, 36, 37). However, there is still a lack of information about the structure and function of IGFBPs associated with CVD.

In our study, we also detected the up-regulation of miR-146b in patients with CVAEs. In a study performed on rats, the authors reported the role of miR-146b during myocardial ischemia/reperfusion injury (IRI) in myocardial I/R rat and hypoxia/reoxygenation (H/R) injured cardiomyocytes. They found that miR-146b overexpression significantly decreased the myocardial infarct size and cardiomyocytes apoptotic rates and release of creatine kinase and lactate dehydrogenase during IRI by targeting Smad4 and modulating the expression of c-fos and c-JUN in the myocardium (31). Another study showed that miR-146b inhibition increased hypoxia-induced cardiomyocyte...
apoptosis, which indicated the potential protective effect of miR-146b in ischemia injury (38). However, the role of miR-146b in myocardial ischemic injury is still unclear (4).

A healthy heart relies primarily on fatty acid oxidation for ATP production, with a smaller contribution from glucose oxidation. In early HF, glucose oxidation increases, and glucose is converted to pyruvate in the cytosol, then transported into the mitochondria, and converted to acetyl Co-A by pyruvate dehydrogenase for ATP production and to lactate by LDHB. Both fatty acid and glucose oxidation are decreased in advanced HF (39–41). In this cohort study, proteomics analysis identified the up-regulation of LDHB in patients who experienced CVAEs. On the other hand, the metabolomics data analysis showed lower level of pyruvate but increased level of lactate in patients with CVAEs. A recent study identified a correlation between LDHB and cardiac hypertrophy and suggested a molecular mechanism for regulating abnormal energy metabolism in cardiac hypertrophy (26). LDHB may be an appropriate target to improve abnormal cardiac energy metabolism in the setting of cardiac hypertrophy.

Based on the integrative analysis of multi-omics data, we identified the association between the pyruvate fermentation to lactate (pyruvate oxidation) pathway and CFZ-CVAEs. Our results highlight the increase in lactate level and decrease of pyruvate level after CFZ administration, which supports the idea that anaerobic glycolysis occurring in myocardial ischemia leads to mitochondrial metabolic dysfunction and reduction in ATP production through oxidative phosphorylation (42, 43). We propose a possible mechanism for the CFZ-CVAEs in

Table 4: MicroRNA up-regulated or down-regulated in MM with or without CVAEs as determined by Open Array fold change <0.5 and ≥1.5.

| miRNA name  | Z score | p-value | Fold change | Regulation |
|-------------|---------|---------|-------------|------------|
| hsa-miR-146b| -2.00   | 0.046   | 14.80       | Up         |
| hsa-miR-342-3p| -1.71   | 0.086   | 6.22        | Up         |
| hsa-miR-19b | -1.71   | 0.086   | 0.51        | Down       |
| hsa-miR-30b | -1.71   | 0.086   | 0.06        | Down       |
| hsa-miR-1274B| -1.29   | 0.199   | 1.76        | Up         |
| hsa-miR-139-5p| -1.29   | 0.199   | 0.03        | Down       |
| hsa-miR-150 | -1.14   | 0.253   | 2.02        | Up         |
| hsa-miR-17  | -1.14   | 0.253   | 0.57        | Down       |
| hsa-miR-195 | -1.14   | 0.253   | 0.15        | Down       |
| hsa-miR-30a-5p| -1.00   | 0.317   | 0.10        | Down       |
| hsa-miR-191 | -0.86   | 0.391   | 4.15        | Up         |
| hsa-miR-331 | -0.71   | 0.475   | 1.81        | Up         |
| hsa-miR-142-3p| -0.71   | 0.475   | 0.20        | Down       |
| hsa-miR-222 | -0.57   | 0.568   | 1.70        | Up         |
| hsa-miR-126 | -0.57   | 0.568   | 1.57        | Up         |
| hsa-miR-30c | -0.43   | 0.668   | 0.47        | Down       |
| hsa-miR-106a| -0.43   | 0.668   | 0.32        | Down       |
| hsa-miR-720 | -0.43   | 0.668   | 0.25        | Down       |
| hsa-miR-483-5p| -0.43   | 0.668   | 0.17        | Down       |
| hsa-miR-21  | -0.29   | 0.775   | 0.32        | Down       |
| hsa-miR-92a | 0.00    | 1.000   | 0.46        | Down       |

Figure 5. A lower level of pyruvate and a higher level of lactate in patients with CVAEs are consistent with cardiomyocytes switching substrate preference from fatty acids to glucose because of mitochondrial dysfunction.

It is important to acknowledge a couple of limitations of our study. First, this was a pilot study with a small sample size selected from a single center. Therefore, the metabolomic, proteomic, and miRNA biomarkers that differentiate MM patients with and without CVAEs need to be further validated before
they can be considered useful clinically. Nevertheless, these preliminary findings point to a plausible pathway that indicates the CFZ-CVAEs might be related to mitochondrial dysfunction. Second, since the plasma samples were obtained after the patients were treated with CFZ, the identified biomarkers have no predictive value. In order to identify clinically useful predictive biomarkers, pre-treatment samples need to be analyzed. However, the differences between patients with and without CVAEs provided essential insights into the mechanisms of CFZ-CVAEs.

In summary, in this pilot multi-omics integrative analysis, we observed the down-regulation of pyruvate and up-regulation of LDHB among patients with CFZ-CVAEs, suggesting the importance of pyruvate oxidation pathway and mitochondrial dysfunction in CFZ-CVAEs. Further investigation in a larger independent cohort is warranted to better understand the mechanisms of CFZ-CVAEs.

DATA AVAILABILITY STATEMENT

The data presented in the study are deposited in the ProteomeXchange Consortium via the PRIDE partner repository, accession number (PXD024281).

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by University of Florida Institutional Review Board. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

MT wrote the manuscript. MT, LC, YH, and YG performed the statistical analyses. TG performed the metabolomics analysis. SS assisted in the pathway analysis. CS, NW, and JM collected the patient samples. YG, RC, RB, MF, DD, LY, TL, KM, and CP provided the critical revision of the manuscript. YG secured the funding for this study. All authors contributed to the article and approved the submitted version.

FUNDING

This research was supported in part by the University of Florida Health Cancer Center and in part by the University of Florida Clinical and Translational Science Institute, which is supported in part by the NIH National Center for Advancing Translational Sciences under award number UL1TR001427.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2021.645122/full#supplementary-material
REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019 (US statistics). CA Cancer J Clin. (2019) 69:7–34. doi: 10.3322/caac.21551
2. Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metast Rev. (2017) 36:561–84. doi: 10.1007/s10555-017-9707-8
3. Hasinoff BB, Patel D, Wu X. Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted drugs bortezomib and carfilzomib. Cardiovasc Toxicol. (2017) 17:237–50. doi: 10.1007/s12110-016-9378-7
4. Efentakis P, Kremastiotis G, Varela A, Nikolaou PE, Papanagou ED, Davos CH, et al. Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood. (2019) 133:710–23. doi: 10.1182/blood-2018-06-858415
5. Teicher BA, Tomaszewski JE. Competitive landscape report. Biochem Pharmacol. (2015) 96:1–9. doi: 10.1016/j.bcp.2015.04.008
6. Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. (2017) 18:1327–37. doi: 10.1016/S1470-2045(17)30578-8
7. Libby E, Garcia D, Quintana D, Fekrazad MH, Bauman J, Ebaid A, et al. Disease-specific survival for patients with multiple myeloma: significant improvements over time in all age groups. Leuk Lymphoma. (2014) 55:2850–7. doi: 10.3109/10428194.2014.897708
8. Kistler KD, Kalman J, Sahni G, Murphy B, Werther W, Rajangam K, et al. Incidence and risk of cardiac events in patients with previously treated multiple myeloma versus matched patients without multiple myeloma: an observational, retrospective, cohort study. Clin Lymphoma, Myeloma Leuk. (2017) 17:89–96.e3. doi: 10.1016/j.jclml.2016.11.009
9. Atrash S, Tullos A, Panozzo S, Bhutani M, Van Rhee F, Barlogie B, et al. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Blood Cancer J. (2015) 5:272. doi: 10.1038/bcj.2014.99
10. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019 (US statistics). CA Cancer J Clin. (2019) 69:7–34. doi: 10.3322/caac.21551
11. Muchtar E, Gatt ME, Rouvio O, Ganzel C, Chubar E, Suriu C, et al. Identification and functional expression of the mitochondrial pyruvate carrier. Science. (2012) 336:93–6. doi: 10.1126/science.1218530
12. Kuo YJ, Wu J, Wang J, Deng Y, Zou G, et al. MicroRNA-375-3p inhibitor suppresses angiotensin II-induced cardiomyocyte hypertrophy by promoting lactate dehydrogenase B expression. J Cell Physiol. (2019) 234:14198–209. doi: 10.1002/jcp.28116
13. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation. (2004) 109:1580–9. doi: 10.1161/01.CIR.0000120390.68287.BB
14. Shimizu I, Minamino T. Physiological and pathological cardiac hypertrophy [Internet]. J Mol Cell Cardiol. (2016) 97:245–62. doi: 10.1016/j.yjmcc.2016.06.001
15. Marcinkiewicz-Siemion M, Ciborowski M, Ptaszynska-Kopcynska K, Szpakowicz A, Lisowska A, Jasiewicz M, et al. LC-MS-based serum fingerprinting reveals significant dysregulation of phospholipids in chronic heart failure. J Pharm Biomed Anal. (2018) 154:354–63. doi: 10.1016/j.jpba.2018.03.027
16. Hoeflich A, David R, Hjorteborg R. Current IGFBP-related biomarker research in cardiovascular disease-We need more structural and functional information in clinical studies. Front Endocrinol. (2018) 9:388. doi: 10.3389/fendo.2018.00388
17. Di YE, Li DC, Shen YQ, Wang CL, Zhang DY, Shang AQ, et al. MiR-146b protects cardiomyocytes injury in myocardial ischemia/reperfusion by targeting Smad4. Am J Transl Res. (2017) 9:656–63.
18. Huynh K, Barlow CK, Jayawardana KS, Weir JM, Mellett NA, Cimel M, et al. High-Throughput plasma lipidomics: detailed mapping of the associations with cardiometabolic risk factors. Cell Chem Biol. (2019) 26:71–84.e4. doi: 10.1016/j.chembiol.2018.10.008
19. Zhu Y, Feng Y, Shen L, Xu D, Wang B, Ruan K, et al. Effect of metformin on the urinary metabolites of diet-induced-obese mice studied by ultra performance liquid chromatography coupled to time-of-flight mass spectrometry (UPLC-TOF/MS). J Chromatogr B Anal Technol Biomed Sci. (2013) 925:110–6. doi: 10.1016/j.jchromb.2012.02.040
20. Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife. (2015) 4:1–38. doi: 10.7554/eLife.05003.028
21. Shahini N, Michelsen AE, Nilsson PH, Ekholk K, Gullesstad I, Broch K, et al. The alternative complement pathway is dysregulated in patients with chronic heart failure. Sci Rep. (2017) 7:1–10. doi: 10.1038/srep42532
22. Berry M, Galinier M, Delmas C, Fournier P, Desmoulin F, Turkeie A, et al. Proteomics analysis reveals IGFBP2 as a candidate diagnostic biomarker for heart failure. JFC Metab Endor. (2015) 6:5–12. doi: 10.1016/j.jicme.2014.11.003
37. Barutaut M, Fournier P, Peacock WF, Evaristi MF, Caubère C, Turkieh A, et al. Insulin-like growth factor binding protein 2 predicts mortality risk in heart failure. *Int J Cardiol.* (2020) 300:245–51. doi: 10.1016/j.ijcard.2019.09.032

38. Li JW, He SY, Feng ZZ, Zhao L, Jia WK, Liu P, et al. MicroRNA-146b inhibition augments hypoxia-induced cardiomyocyte apoptosis. *Mol Med Rep.* (2015) 12:6903–10. doi: 10.3892/mmr.2015.4333

39. Fillmore N, Mori J, Lopaschuk GD. Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. *Br J Pharmacol.* (2014) 171:2080–90. doi: 10.1111/bph.12475

40. Lionetti V, Stanley WC, Recchia FA. Modulating fatty acid oxidation in heart failure. *Cardiovasc Res.* (2011) 90:202–9. doi: 10.1093/cvr/cvr038

41. Li X, Liu J, Lu Q, Ren D, Sun X, Rousselle T, et al. AMPK: A therapeutic target of heart failure—not only metabolism regulation. *Biosci Rep.* (2019) 39:1–13. doi: 10.1042/BSR20181767

42. Barry WH. Heart physiology from cell to circulation, 4th ed. *Circulation.* (2004) 110:e313. doi: 10.1161/01.CIR.0000143724.99618.62

43. Stanley W. Changes in cardiac metabolism: a critical step from stable angina to ischaemic cardiomyopathy. *Eur Heart J Suppl.* (2001) 3:02–7. doi: 10.1016/S1520-765X(01)90147-6

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.